New pill design aims to smooth out Parkinson's drug levels

NCT ID NCT05471609

Completed Knowledge-focused Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a new oral version of the Parkinson's drug levodopa/carbidopa designed to release the medication slowly over time. Six healthy volunteers took the drug to see if it could keep steady levels in the blood. The goal is to reduce the 'on-off' motor fluctuations that many Parkinson's patients experience with standard pills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

levodopa/carbidopa

What this could lead to

If successful, this formulation could help Parkinson's patients maintain more stable drug levels, potentially reducing motor fluctuations.

What could go wrong

This is a very early, small study in only 6 healthy people, not Parkinson's patients. It only measures drug levels, not actual symptom control, so real-world benefits are uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Locations

University of Minnesota

Minneapolis, Minnesota, 55455, United States